3rd ADC Target Selection Summit Hilton Boston Logan Airport, Boston

With the number of new clinical ADC targets reaching an all-time high, the 3rd ADC Target Selection Summit returns as the only industry-specific meeting spotlighting the latest developments in the field that will continue progressing first- and best-in-class ADCs through the clinic.

Providing a greater focus on identifying and validating novel targets, re-examining what makes a good target, and analyzing how novel linker-payload technologies are changing the target selection paradigm; this is your unique opportunity to delve into the use of proteomics to ensure you get the first step of drug development right.

With 100+ ADC enthusiasts set to be in the room including Iksuda Therapeutics, Merck and Co, Angiex, Ziel Bio, and Seagen; this is your chance to connect with peers working exclusively in biology, discovery, translational, target identification and validation.

Facilitating conversations on both the scientific and strategic elements of target selection for antibody-drug conjugates, this meeting will address all important discussions to inform your target selection and balance risk in your ADC pipeline for 2024 and beyond.